Genmab AS (STU:GE9) 5-Year EBITDA Growth Rate : 26.20% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab AS 5-Year EBITDA Growth Rate?

Genmab AS's EBITDA per Share for the three months ended in Sep. 2024 was €3.88.

During the past 12 months, Genmab AS's average EBITDA Per Share Growth Rate was 28.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -1.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 26.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 45.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Genmab AS was 130.50% per year. The lowest was -6.80% per year. And the median was 33.00% per year.

Competitive Comparison of Genmab AS's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Genmab AS's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Genmab AS's 5-Year EBITDA Growth Rate falls into.

Genmab AS 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Genmab AS (STU:GE9) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Genmab AS 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Genmab AS's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines